Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

241
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
241
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

207
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
207
Imaging Studies II: Ultrasonography01:24

Imaging Studies II: Ultrasonography

289
IntroductionUltrasonography, or renal ultrasound, is a noninvasive medical imaging technique that uses high-frequency sound waves to visualize the kidneys, ureters, bladder, and surrounding tissues.Indications for Urinary System UltrasonographyUrinary system ultrasonography is indicated in various clinical scenarios, such as:Kidney Stones (Urolithiasis): To detect and monitor the size and presence of kidney or urinary tract stones.Hydronephrosis: To assess the dilation of the renal pelvis and...
289
Radiological Investigation II: MRI and Ventilation Perfusion Scan01:30

Radiological Investigation II: MRI and Ventilation Perfusion Scan

476
Description
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
476
Radiological Investigation I: X-ray and CT01:30

Radiological Investigation I: X-ray and CT

985
Radiological investigations, including X-rays and computed tomography (CT) scans, are critical for diagnosing and evaluating various medical conditions. These imaging techniques provide valuable insights into the body's internal structures, aiding in the detection of abnormalities, assessment of disease progression, and development of treatment strategies. This article delves into two primary radiological investigations, chest X-rays and CT scans, outlining their purpose, procedures, and...
985
Imaging Studies I: Kidney, Ureter, and Bladder Studies01:28

Imaging Studies I: Kidney, Ureter, and Bladder Studies

221
Kidney, Ureter, and Bladder (KUB) StudiesKidney, Ureter, and Bladder (KUB) studies are standard diagnostic imaging procedures used to assess the anatomy of the urinary system. They are commonly utilized for patients experiencing abdominal pain or urinary symptoms. By using a simple X-ray of the abdomen, KUB studies can reveal structural and pathological abnormalities within the kidneys, ureters, and bladder. These studies are particularly valuable in diagnosing kidney stones, urinary...
221

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same author

<i>APOE</i>-associated disease risk and sex-specific effects in Egyptian Alzheimer's disease: an exploratory study.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Outcome-specific risk factors challenge universal dementia prevention priorities: Findings from the Egyptian Dementia Network Registry.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Future oncology (London, England)·2026
Same author

Development and Validation of Quality of Life in Idiopathic Intracranial Hypertension (QOLIH) questionnaire.

Frontiers in neurology·2026
Same author

Upper tract urothelial carcinoma associated with Lynch syndrome.

Current opinion in oncology·2026

Related Experiment Video

Updated: Jan 4, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.8K

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

Andrea B Apolo1, Matthew I Milowsky2, Lauren Kim1

  • 1National Institutes of Health, Bethesda, Maryland.

JAMA Oncology
|November 1, 2019
PubMed
Summary

Harmonizing eligibility and radiographic assessments for muscle-invasive bladder cancer (MIBC) adjuvant trials is crucial. This ensures consistent interpretation of results for better treatment advancements in MIBC clinical research.

More Related Videos

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.1K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.9K

Related Experiment Videos

Last Updated: Jan 4, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.8K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.1K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.9K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Urologic Oncology

Background:

  • Muscle-invasive bladder cancer (MIBC) clinical trials require standardized eligibility criteria and radiographic assessments.
  • Adjuvant therapy trials for MIBC have lacked uniformity, hindering result interpretation.

Purpose of the Study:

  • To harmonize eligibility criteria and radiographic disease assessments in clinical trials of adjuvant therapy for muscle-invasive bladder cancer (MIBC).

Main Methods:

  • A public workshop convened national experts in bladder cancer clinical trial research.
  • Discussions focused on eligibility, radiographic entry criteria, and disease recurrence assessment in MIBC adjuvant trials.

Main Results:

  • Recommendations include allowing enrollment for urothelial carcinoma with divergent differentiation and upper-tract MIBC.
  • Defined neoadjuvant chemotherapy and criteria for patients with renal insufficiency or microscopic margins.
  • Standardized imaging protocols (CT within 4 weeks) and evaluation of indeterminate lesions were proposed.
  • Uniform approaches to defining recurrence events and 'no evidence of disease' were established.

Conclusions:

  • Harmonized eligibility criteria and definitions of disease recurrence can lead to more consistent interpretations of adjuvant trial results in MIBC.
  • Standardization is essential for advancing the understanding and treatment of muscle-invasive bladder cancer.